Stifel analyst Stephen Willey lowered the firm's price target on Abeona Therapeutics to $19 from $20 and keeps a Buy rating on the shares. Management's temporary pause on patient biopsy collection sets back the commercial launch by about three months and decreases confidence in the firm's now-lower Q4 estimate as a result of the temporal uncertainty associated with the timing of revenue recognition, the analyst tells investors in a research note. The firm added that increasing patient demand strengthens its confidence in FY26 and beyond, and believes the set-up here offers an attractive risk/reward.
